[Beta blockers in hypertension treatment Will stepping back come soon?].
Sawicki
Peter T
PT
Instituts für Qualität und Wirtschaftlichkeit in der Medizin.
Anlauf
Manfred
M
Haller
Hermann
H
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000367:Age Factors; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001262:Atenolol / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004232:Diuretics / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D015201:Meta-Analysis as Topic; D008790:Metoprolol / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D012307:Risk Factors; D013565:Sympatholytics / Q000008:administration & dosage / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D004232:Diuretics; D013565:Sympatholytics; D001262:Atenolol; D008790:Metoprolol